Our news journalists obtained a quote from the research from the University of Catania, "Topical administration of these drugs is always the best choice since adverse effects occur commonly with systemic NSAID therapy. For more information on this research see: Emerging Role of Colloidal Drug Delivery Systems in NSAID Topical Administration. Curren
Dublin- Research and Markets has announced the addition of the "Injectable Drug Delivery to 2018 Drugs, Devices, Targets, Therapeutics and Forecasts" report to their offering. The past decade has seen a dramatic shift in terms of the types of approved injectable drugs, the diseases they target, and the devices used to deliver them. This shift has f
Dublin- Research and Markets has announced the addition of the "Pen Injectors Devices, Drugs, Combination Products" report to their offering. User-friendly designs and the availability of an increasing number of drugs in pre-filled disposable cartridges and syringes are propelling the growth of injector pens at the expense of other drug delivery me
Dublin- Research and Markets has announced the addition of the "Prefilled Syringes to 2018 Devices, Drugs, Markets, Players and Prospects" report to their offering. The administration of therapeutic drugs via injection is an indispensable delivery method for numerous drugs critical to patient health and well-being. Now this segment is evolving in r
Dublin- Research and Markets has announced the addition of the "Transdermal Drug Patches to 2018 Products, Indications, Markets and Forecasts" report to their offering. Transdermal drug patches offer the advantages of ease of use, painlessness, disposability, control of drug delivery and avoidance of first-pass metabolism by the liver. Advances in
Cynapsus Therapeutics Inc., developing the only non-injectable delivery of the only approved drug to be used as a rescue therapy for "off" motor symptoms of Parkinson's disease, today announced its results for the three months ended March 31, 2013. As previously announced, in March 2013 the Company successfully raised $7.3 million, converted $4 mil
As part of the company's push to carve out a share of the $142 billion U.S. drug delivery market, Rainbow Coral Corp. said that it has opened talks this week to potentially partner with an emerging innovator in the transdermal delivery sector. Some analysts have predicted that the transdermal delivery market could be worth as much as $31.5 billion
According to news reporting out of Warangal, India, by NewsRx editors, research stated, "Fast-dissolving drug-delivery systems were first developed in the late 1970 s as an alternative to tablets, capsules, and syrups for pediatric and geriatric patients who experience difficulties swallowing traditional oral solid dosage forms. Our news journalist
As part of the company s push to carve out a share of the $142 billion U.S. drug delivery market, Rainbow Coral Corp. opened talks this week to potentially partner with an emerging innovator in the transdermal delivery sector. RBCC formed a biotech subsidiary, Rainbow BioSciences, to market and develop new medical and research technology innovat
Pre-filled syringes and related devices- discover companies' revenue prospects. How are companies in the pre-filled syringe industry performing? Visiongain's report gives you data, analyses and discussions for producers of those drug delivery devices.
Research and Markets has announced the addition of the "Injectable Drug Delivery Market by Formulations, Devices& Therapeutics- Global Forecasts to 2017" report to its offerings. In a release, Research and Markets noted that report highlights include:. The global injectable drug delivery technologies market was valued at $22.5 billion in 2012, and
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that the United States Food and Drug Administration has cleared the Company's Investigational New Drug application for ORMD-0801, its oral insulin capsule. "We are very pleased to have the FDA clearance to proceed," stated Nadav Kidron, CEO of Oramed. Oramed...
